CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer
2024
CRISPR/Cas9 Technology in Metastatic Prostate Cancer Treatment
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Park Jieun, Kim Jaehong
Primary Institution: Dongguk University, Gachon University
Hypothesis
Can CRISPR/Cas9 technology enhance the treatment of metastatic prostate cancer?
Conclusion
CRISPR/Cas9 technology has the potential to improve treatment outcomes for metastatic prostate cancer by targeting specific genetic mutations.
Supporting Evidence
- Prostate cancer is the most common cancer in men and often spreads to other organs.
- CRISPR/Cas9 can target genes involved in cancer metastasis.
- Current therapies for prostate cancer have limitations, especially in advanced stages.
Takeaway
Scientists are exploring a tool called CRISPR to help treat prostate cancer by fixing the genes that cause the cancer to spread.
Methodology
This review analyzes existing literature on metastatic prostate cancer and the application of CRISPR/Cas9 technology in its treatment.
Limitations
The review does not include ongoing clinical trials using CRISPR technology for prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website